About the Company
Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AKCA News
An Intrinsic Calculation For Akcea Therapeutics, Inc. (NASDAQ:AKCA) Suggests It's 48% Undervalued
Today we will run through one way of estimating the intrinsic value of Akcea Therapeutics, Inc. (NASDAQ:AKCA) by projecting its future cash flows and then discounting them to today's value.
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.
TNYA Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular ...
DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company ...
Lexeo Therapeutics Inc LXEO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Leap Therapeutics Inc LPTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Avenue Therapeutics Inc (ATXI)
In a strategic move, Avenue Therapeutics Inc . (NASDAQ: NASDAQ:ATXI) has announced a reverse stock split, as per a recent 8K SEC filing. Effective Tuesday, the majority of the ...
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
Warning! GuruFocus has detected 4 Warning Signs with RGLS. On March 21, 2024, Regulus Therapeutics Inc (NASDAQ:RGLS) released its 8-K filing, detailing its financial results for the fourth quarter ...
Q4 2023 Cognition Therapeutics Inc Earnings Call
Lisa Ricciardi; President, CEO; Cognition Therapeutics, Inc. John Doyle; CFO; Cognition Therapeutics, Inc. Tony Caggiano; Chief Medical Officer; Cognition ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034
Treatment for particular genetic defects can be personalized with antisense and RNA interference therapies. The ability to ...
Loading the latest forecasts...